Monoclonal Antibody Development
Leinco Technologies scientific staff has extensive monoclonal antibody development experience and offers clients the opportunity to collaborate on the development of antibodies against soluble proteins, cell surface molecules, or haptens for use in detection, neutralization or in vivo depletion. Through the use of proprietary development technologies, Leinco has demonstrated success in developing monoclonal antibodies against single amino acid substitutions, splice variants and for neutralization.
Superior mAB Performance
Leinco Technologies is one of a few biotechnology companies that offer monoclonal antibody development using both mice or hamsters as host animals. Importantly, the use of hamster as the host animal offers the unique advantage of an antibody that can be used in vivo in the mouse model without eliciting an immune response against the injected antibody. The applications of antibodies developed at Leinco Technologies include early discovery research, in vivo preclinical therapeutic investigations, and in vitro diagnostics.
Phases of Hybridoma Cell Line Development
Hybridoma cell line development consists of four (4) phases including immunization, fusion, cloning and In vitro antibody production. A protein or peptide based project typically requires 4 – 6 mg of soluble antigen. Upon successfully developing a panel of stable hybridoma cell lines, included and at no additional cost is the further characterization of secreted monoclonal antibodies and small-scale production. In addition, clients receive at the conclusion of each project complete documentation of all phases and a development summary.